Myriad Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Myriad Bundle
Visual. Strategic. Downloadable.
Uncover the strategic positioning of this company's product portfolio with our insightful BCG Matrix preview. See how its offerings stack up as Stars, Cash Cows, Dogs, or Question Marks, and understand the implications for future growth. Purchase the full BCG Matrix for a comprehensive breakdown, data-driven recommendations, and a clear roadmap to optimize your investments and product strategy.
Stars
MyRisk with RiskScore for Oncology
Myriad's MyRisk with RiskScore is a standout performer in the oncology market, showcasing robust leadership in hereditary cancer testing. This test is a significant contributor to Myriad's overall success.
The demand for MyRisk with RiskScore in oncology is clearly on the rise. For the second quarter of 2025, testing volume saw a healthy 14% increase compared to the same period in 2024. This growth highlights its strong market penetration and the increasing need for such diagnostic tools.
Precise MRD Test Development
The Precise Molecular Residual Disease (MRD) test is a standout performer for Myriad, addressing a rapidly expanding market. This segment is expected to grow from $1.87 billion in 2024 to $3.54 billion by 2030, showcasing significant upside potential.
Myriad's Precise MRD test is designed for ultra-sensitivity and can be applied across various cancer types, positioning it strongly to gain considerable market share in this burgeoning field.
The unveiling of new clinical data in May 2025 will further underscore the innovative nature and high potential of this critical diagnostic tool.
Overall Oncology Hereditary Cancer Segment
Myriad's hereditary cancer testing segment, a cornerstone of its oncology offerings, demonstrated impressive growth. In the second quarter of 2025, this segment, which includes key products like MyRisk and BRACAnalysis, saw its revenue climb by 9% compared to the same period in the prior year.
This strong performance underscores Myriad's significant market share within the rapidly expanding precision oncology landscape. The company's strategic commitment to the Cancer Care Continuum further solidifies its position and ongoing investment in this critical area of healthcare.
Strategic Investments in AI-Enabled Diagnostics
Myriad's strategic investments in AI-enabled diagnostics, such as its collaboration with PATHOMIQ for prostate cancer detection, position it to capture growth in the burgeoning oncology market. These initiatives, though potentially in their nascent stages, target high-potential areas within cancer diagnostics. By focusing on these advanced technologies, Myriad aims to solidify its future market leadership and ensure continued expansion.
These AI-driven diagnostic tools are not just about innovation; they're about tangible improvements in patient care and market differentiation. For example, AI in pathology can significantly speed up diagnosis and improve accuracy, a critical factor in cancer treatment. The global AI in healthcare market was valued at approximately $15.4 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of over 37% from 2024 to 2030, indicating a substantial opportunity for companies like Myriad investing in this space.
- AI in Diagnostics: Myriad's partnership with PATHOMIQ for AI-powered prostate cancer diagnostics.
- Market Potential: Targeting high-growth oncology segments with advanced diagnostic solutions.
- Future Growth: Investments aimed at securing future market leadership and sustained revenue streams.
- Industry Growth: The AI in healthcare market is a rapidly expanding sector, projected for significant growth.
Expansion of Hereditary Cancer Testing for Affected Individuals
Myriad Genetics is strategically expanding its hereditary cancer testing services, particularly for individuals already diagnosed with cancer. This focus goes beyond their established MyRisk test with RiskScore, targeting the oncology patient population where genetic information directly influences treatment pathways and therapeutic choices.
This concentrated effort leverages Myriad's existing strong market position in hereditary cancer testing. By deepening their penetration within the affected patient segment, they aim to become an indispensable partner in oncology care, where genetic insights are increasingly critical for personalized medicine.
The company's sustained investment in this area is a key driver for maintaining its high market share and achieving continued growth. This strategic direction is supported by the growing understanding of how hereditary cancer predispositions impact treatment efficacy and patient outcomes.
- Market Penetration: Myriad aims to increase its share within the oncology patient population by offering advanced hereditary cancer testing.
- Treatment Guidance: Genetic insights from these tests are vital for oncologists in making informed treatment decisions for cancer patients.
- Investment Focus: Continued investment in this segment is expected to solidify Myriad's leadership and drive future revenue growth.
- Oncology Integration: The expansion aligns with the broader trend of integrating genetic testing into routine cancer care protocols.
Myriad's High-Growth Products Drive Oncology Advancements
Myriad's Stars, representing its most promising and high-growth products, include MyRisk with RiskScore and the Precise Molecular Residual Disease (MRD) test. These products are at the forefront of precision oncology, addressing critical needs in cancer diagnosis and management.
The hereditary cancer testing segment, featuring MyRisk, saw a 9% revenue increase in Q2 2025 year-over-year, demonstrating strong market traction. The Precise MRD test is positioned to capitalize on the expanding MRD market, projected to reach $3.54 billion by 2030 from $1.87 billion in 2024.
Myriad's strategic focus on AI-enabled diagnostics further bolsters its Star products, with AI in healthcare market growth anticipated at over 37% CAGR from 2024-2030. These investments are crucial for maintaining market leadership and driving future revenue.
| Product | Market Segment | Q2 2025 Growth (YoY) | Market Size (2024) | Projected Market Growth (CAGR) |
|---|---|---|---|---|
| MyRisk with RiskScore | Hereditary Cancer Testing | 9% | N/A | N/A |
| Precise MRD Test | Molecular Residual Disease | N/A | $1.87 billion | 37%+ (AI in Healthcare Market) |
What is included in the product
Detailed Word Document
The Myriad BCG Matrix offers a strategic overview of a company's product portfolio, categorizing units into Stars, Cash Cows, Question Marks, and Dogs.
This framework guides decisions on investment, divestment, and resource allocation for optimal business growth.
Customizable Excel Spreadsheet
Clear visual of your portfolio's strengths and weaknesses.
Cash Cows
Established Prenatal Testing Portfolio
Myriad's established prenatal testing portfolio, featuring products like Foresight and Prequel, continues to be a significant revenue driver for the company. This segment holds a strong market position in a mature, yet stable, industry.
Despite a temporary dip in order volume in Q2 2025 attributed to a system issue, the prenatal testing business demonstrated resilience. Revenue saw a 7% year-over-year increase in Q2 2025, following an impressive 11% growth in Q1 2025, underscoring its cash cow status.
Core Hereditary Cancer Testing for Unaffected Population
Myriad's core hereditary cancer testing for the unaffected population acts as a classic cash cow. These established tests, designed for risk assessment, provide a stable and foundational revenue stream for the company.
While the growth for these offerings is more measured, projected at 1-3% volume and revenue growth in Q2 2025, they command a significant market share. This strong market position allows them to generate consistent cash flow, requiring minimal additional investment to maintain their performance.
High Gross Margins from Lab Efficiencies
Myriad's commitment to operational excellence has translated into significant laboratory efficiencies, a key driver for its robust financial performance. This focus on streamlining processes allows the company to achieve impressive adjusted gross margins, which stood at 71.5% in the second quarter of 2025.
These high margins on its established product lines clearly demonstrate their status as cash cows. The company is effectively leveraging its operational strengths to generate substantial profits from these mature offerings, allowing it to maximize returns from existing investments.
BRACAnalysis and BRACAnalysis CDx
BRACAnalysis and BRACAnalysis CDx represent Myriad Genetics' established "cash cows" within the BCG matrix framework. These pioneering tests for hereditary cancer have carved out a significant market share, benefiting from strong brand recognition built over years of reliable performance.
While these products may be considered in a more mature stage, they consistently generate substantial and dependable cash flow for Myriad. This financial stability is crucial, underpinning the company's ability to invest in research and development for newer, potentially high-growth products.
- Market Leadership: BRACAnalysis was a first-of-its-kind test, establishing Myriad as a leader in hereditary cancer diagnostics.
- Consistent Revenue: These tests continue to be a primary revenue driver, contributing significantly to Myriad's financial health.
- Foundation of Business: They form the bedrock of Myriad's diagnostic portfolio, supporting innovation in other areas.
- Brand Loyalty: Decades of clinical use have fostered trust and loyalty among healthcare providers and patients.
Stable Revenue from Women's Health Segment
Myriad's Women's Health segment, encompassing prenatal and hereditary cancer tests for individuals without a current diagnosis, is a significant contributor to its financial stability. In the second quarter of 2025, this business unit generated an impressive $89.8 million in revenue.
This segment is characterized by its consistent performance and enduring demand, making it a dependable source of cash flow for Myriad. The predictable nature of these services underpins its classification as a Cash Cow within the BCG Matrix.
- Women's Health Revenue (Q2 2025): $89.8 million
- Key Offerings: Prenatal tests, hereditary cancer tests for unaffected individuals
- Performance Characteristic: Stable revenue and consistent demand
- BCG Matrix Classification: Cash Cow
Cash Cows: Stable Revenue Streams
Myriad's established hereditary cancer testing, particularly BRACAnalysis and BRACAnalysis CDx, are prime examples of Cash Cows. These pioneering tests have secured a dominant market share, fueled by decades of clinical use and strong brand recognition.
These mature offerings consistently generate substantial, dependable cash flow, which is crucial for funding Myriad's research and development in newer, high-growth areas. Their stable revenue stream, despite more measured growth projections, highlights their foundational importance to the company's financial health.
The Women's Health segment, including prenatal and hereditary cancer tests for unaffected individuals, also functions as a Cash Cow. This segment posted $89.8 million in revenue in Q2 2025, demonstrating stable performance and consistent demand.
The company's operational efficiencies, contributing to a 71.5% adjusted gross margin in Q2 2025, further bolster the profitability of these established product lines, solidifying their Cash Cow status.
| Product/Segment | BCG Classification | Q2 2025 Revenue | Projected Growth (2025) | Key Characteristic |
|---|---|---|---|---|
| BRACAnalysis/BRACAnalysis CDx | Cash Cow | N/A (Part of Women's Health) | 1-3% | Market leader, consistent cash flow |
| Prenatal Testing (Foresight, Prequel) | Cash Cow | N/A (Part of Women's Health) | N/A | Stable, resilient revenue driver |
| Women's Health (Overall) | Cash Cow | $89.8 million | N/A | Dependable, predictable cash flow |
What You’re Viewing Is Included
Myriad BCG Matrix
The preview you're viewing is the identical, fully functional Myriad BCG Matrix document you'll receive upon purchase. This means no watermarks, no demo content, and no hidden surprises – just the complete, professionally formatted strategic tool ready for immediate implementation. You can confidently assess its value and utility, knowing the purchased version will be exactly the same, enabling seamless integration into your business planning and decision-making processes.
Dogs
Divested EndoPredict Business
Myriad Genetics' divestiture of its international EndoPredict business in August 2024 firmly places this segment within the 'dog' quadrant of the BCG matrix. This strategic move signals that EndoPredict was viewed as a low-growth, low-market share asset that no longer fit Myriad's evolving business priorities.
Divesting 'dogs' is a common and prudent strategy to free up capital and management attention for more promising ventures. In 2023, Myriad's oncology segment, which included EndoPredict, saw revenue of $189.7 million, a slight decrease from $190.2 million in 2022, underscoring the stagnant performance.
Legacy Tumor Profiling Tests
Legacy tumor profiling tests, distinct from newer ventures like Precise Tumor, are experiencing a revenue downturn for Myriad. This strategic shift reflects a focus on more promising areas within their diagnostic offerings.
In the first two quarters of 2025, this segment saw a revenue contraction of 4-5% compared to the previous year. This data points to a shrinking market presence for these established tests within Myriad's overall business.
Underperforming Hereditary Cancer Tests
While Myriad's hereditary cancer testing is a core strength, certain niche tests within this category might be classified as dogs. These could be tests with limited clinical utility or facing intense competition, leading to low market penetration and minimal revenue contribution. For instance, a test for a very rare hereditary cancer syndrome might fall into this quadrant, consuming R&D and marketing resources without significant uptake.
Products Impacted by Sustained Reimbursement Challenges
Products facing ongoing reimbursement issues, like those seen with certain biosimil drugs in the US market during 2024, often find themselves in the 'dog' quadrant of the BCG matrix. These challenges, stemming from payer policies and pricing pressures, can significantly diminish profitability. For instance, some biosimil manufacturers reported lower-than-anticipated reimbursement rates in 2024, impacting their ability to recoup development costs.
When a product line experiences sustained negative changes in payer coverage or reimbursement rates without effective countermeasures, it naturally moves towards the 'dog' category. This situation is exacerbated when profitability is squeezed, making further investment unappealing. By mid-2024, several pharmaceutical products in niche therapeutic areas were reportedly struggling with declining reimbursement, pushing their market viability into question.
- Biosimilar Adoption Rates: In 2024, while biosimilar adoption continued to grow, reimbursement challenges for specific products, particularly in the European market, led to lower-than-expected revenue streams for manufacturers.
- Orphan Drug Reimbursement: Some rare disease treatments, despite critical patient need, faced hurdles in securing favorable reimbursement in 2024, impacting their market share and profitability.
- Medical Device Reimbursement: New medical technologies in 2024 continued to grapple with establishing adequate reimbursement codes and rates, potentially categorizing early adopters as 'dogs' if these issues persist.
Non-Strategic or Outdated Offerings
Myriad's strategic pivot towards its Cancer Care Continuum means that some older or non-essential products are now classified as dogs. These offerings, while perhaps covering their costs, lack the potential for significant future expansion or market differentiation.
For instance, if Myriad's 2024 revenue from a particular genetic test for a less common condition showed minimal growth, say only 1% year-over-year, and market analysts project only a 2% CAGR for that niche segment through 2029, it would likely be categorized as a dog. This is especially true if R&D investment in this area has been curtailed in favor of oncology advancements.
- Non-Core Products: Offerings that don't align with the Cancer Care Continuum strategy.
- Low Growth Potential: Products with minimal projected future revenue increases.
- Limited Competitive Advantage: Offerings that do not provide a distinct edge in the market.
- Stagnant Market Share: Products that are not gaining traction or increasing their presence.
Identifying the "Dogs" in a Diagnostics Portfolio
Dogs represent business units or products with low market share and low growth potential, often draining resources without significant returns. Myriad Genetics' divestiture of its international EndoPredict business in August 2024 exemplifies this classification, as it was a low-growth, low-market share asset. Legacy tumor profiling tests, facing revenue downturns and a focus on newer ventures, also fit this category, with a segment seeing a 4-5% revenue contraction in the first half of 2025.
| Product/Segment | BCG Quadrant | 2023 Revenue (Approx.) | 2024/2025 Trend | Strategic Implication |
|---|---|---|---|---|
| EndoPredict (International) | Dog | N/A (Divested) | Divested Aug 2024 | Capital reallocation |
| Legacy Tumor Profiling | Dog | Part of $189.7M Oncology (2023) | Revenue Downturn / Contracting | Focus shift to newer diagnostics |
| Niche Hereditary Cancer Tests | Potential Dog | Low Contribution | Limited uptake/competition | Resource optimization |
| Products with Reimbursement Issues | Potential Dog | Varies | Declining payer coverage | Profitability pressure |
Question Marks
GeneSight Pharmacogenomics Test
The GeneSight pharmacogenomics test exemplifies a Question Mark within the BCG Matrix. It competes in the rapidly expanding pharmacogenomics sector, a market poised for significant growth. However, GeneSight's position is precarious due to substantial hurdles in capturing market share and generating consistent revenue, largely stemming from adverse changes in payer policies.
Recent financial performance underscores these challenges. For the first quarter of 2025, GeneSight experienced a 20% year-over-year revenue decline. This downward trend continued into the second quarter of 2025, with revenue falling by 12% compared to the same period in the prior year. A primary driver for this contraction has been UnitedHealthcare's decision to reduce coverage for the test.
Given these circumstances, Myriad Genetics faces a critical strategic decision regarding GeneSight. The company must consider a significant investment strategy to revitalize market share and improve its competitive standing. Alternatively, a divestment of the GeneSight asset might be a more prudent course of action to reallocate resources to more promising areas.
Newly Launched Oncology Tests
Myriad's pipeline features promising new oncology tests, such as Precise Liquid, designed to capture lucrative segments in cancer diagnostics. These innovative offerings are currently in their nascent stages, reflecting a low market share.
Significant investment is necessary for their commercialization and widespread adoption, positioning them as question marks within the BCG matrix. This strategic focus aims to nurture these tests into future market leaders, or 'Stars'.
Early-Stage Strategic Partnerships
Early-stage strategic partnerships, like Myriad's AI collaboration with PATHOMIQ for prostate cancer detection, are essentially bets on future breakthroughs. These ventures are in their infancy, meaning they have minimal current market presence. Their ultimate success is tied to substantial future funding and widespread adoption by the market.
Prenatal Tests Affected by Operational Issues
Myriad's prenatal testing business, despite robust market demand, faced a significant hurdle in the second quarter of 2025. A decline of 7-8% in testing volumes was directly linked to operational disruptions stemming from the implementation of a new order management system.
This situation places prenatal testing within the Question Marks quadrant of the BCG Matrix. It highlights a product with substantial market potential, yet its current market share is suppressed due to internal, addressable operational challenges rather than a lack of market interest.
- High Market Potential: The prenatal testing market continues to show strong underlying demand.
- Operational Disruption: A new order management system led to a 7-8% volume decline in Q2 2025.
- Question Marks Classification: The product exhibits high potential but faces current growth limitations due to internal issues.
- Strategic Focus: Myriad needs to resolve the system issues to capitalize on the market opportunity.
Products in Research & Development Pipeline
Myriad's commitment to innovation is evident in its substantial investment in research and development for novel products, especially those aimed at the burgeoning field of precision medicine. These ventures are classified as question marks in the BCG matrix because, while they operate in markets with significant growth potential, they currently hold minimal to no market share. This necessitates considerable capital infusion and strategic attention to ascertain their long-term success and market position.
For instance, Myriad's ongoing efforts in developing advanced genetic testing solutions for rare diseases exemplify this category. In 2024, the company allocated approximately 20% of its operating expenses towards R&D, with a significant portion directed towards these early-stage pipeline products. The success of these question mark products is crucial for Myriad's future growth, as they aim to capture emerging market opportunities and diversify its revenue streams.
- High-Growth Potential Markets: Myriad's R&D pipeline focuses on areas like oncology and autoimmune diseases, which are projected to see substantial market expansion in the coming years. For example, the global precision medicine market was valued at over $600 billion in 2023 and is expected to grow at a CAGR of more than 10% through 2030.
- Low Market Share: These new products are in their nascent stages, meaning they have not yet established a significant customer base or market penetration. This is typical for R&D projects that are still undergoing clinical trials or awaiting regulatory approval.
- Capital Intensive: Bringing new diagnostic tests and therapies to market requires extensive funding for research, development, clinical validation, and regulatory submissions. Myriad's 2024 R&D budget reflects this, with significant outlays for these promising but unproven ventures.
- Strategic Focus Required: Myriad must carefully manage these question mark products, deciding which to invest further in to potentially transform them into stars, and which to divest if they fail to gain traction or meet development milestones.
Question Marks: High Growth, Uncertain Futures
Question Marks represent business units or products with low market share in high-growth industries. They require significant investment to increase market share, with the potential to become Stars or Dogs. Myriad Genetics' GeneSight, new oncology tests like Precise Liquid, and early-stage AI collaborations all fit this description.
The company's prenatal testing business, despite strong market demand, currently exhibits Question Mark characteristics due to recent operational disruptions impacting volumes. Myriad's overall R&D investment, particularly in precision medicine and rare diseases, highlights a portfolio of potential future leaders that are currently in their infancy.
| Product/Initiative | Market Growth | Current Market Share | Strategic Consideration |
|---|---|---|---|
| GeneSight | High | Low (declining due to payer policy changes) | Significant investment for revitalization or divestment |
| Precise Liquid (Oncology Test) | High | Low (nascent stage) | Investment for commercialization and adoption |
| AI Collaborations (e.g., PATHOMIQ) | High | Very Low (infancy) | Nurturing through funding and market adoption |
| Prenatal Testing | High | Suppressed (due to operational issues) | Resolve system issues to capture market potential |
| R&D Pipeline (Precision Medicine, Rare Diseases) | High | Minimal/None | Substantial capital infusion for development and market entry |
BCG Matrix Data Sources
Our BCG Matrix is built on verified market intelligence, combining financial data, industry research, official reports, and expert commentary to ensure reliable, high-impact insights.
